摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

(5-methyl-3-phenylsulfonyl-pyrazolo[1,5-a]pyrimidin-2-yl)-methyl-amine | 1220643-97-9

中文名称
——
中文别名
——
英文名称
(5-methyl-3-phenylsulfonyl-pyrazolo[1,5-a]pyrimidin-2-yl)-methyl-amine
英文别名
N-Methyl-N-[5-methyl-3-(phenylsulfonyl)pyrazolo[1,5-A]pyrimidin-2-YL]amine;3-(benzenesulfonyl)-N,5-dimethylpyrazolo[1,5-a]pyrimidin-2-amine
(5-methyl-3-phenylsulfonyl-pyrazolo[1,5-a]pyrimidin-2-yl)-methyl-amine化学式
CAS
1220643-97-9
化学式
C14H14N4O2S
mdl
MFCD32685292
分子量
302.357
InChiKey
LLRSKWJLJFTWMG-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    2.4
  • 重原子数:
    21
  • 可旋转键数:
    3
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.14
  • 拓扑面积:
    84.7
  • 氢给体数:
    1
  • 氢受体数:
    5

反应信息

  • 作为产物:
    参考文献:
    名称:
    Synthesis and SAR of 3-arylsulfonyl-pyrazolo[1,5-a]pyrimidines as potent serotonin 5-HT6 receptor antagonists
    摘要:
    Syntheses of a series of novel 3-sulfonyl-pyrazolo[1,5-a]pyrimidines and their 5-HT6 receptor antagonistic structure-activity relationship are disclosed. The nature and position of substituents, which affect their receptor antagonistic activity, are analyzed. Among all synthesized derivatives, {3-(3-chlorophenylsulfonyl)-5,7-dimethyl-pyrazolo[1,5-a]pyrimidin-2-yl}-methyl-amine 33 (K-i = 190 pM), (3-phenylsulfonyl-7-methyl-pyrazolo[1,5-a]pyrimidin-2-yl)-methyl-amine 44 (K-i = 240 pM), (3-phenylsulfonyl-5-metoxymethyl-7-methyl-pyrazolo[1,5-a]pyrimidin-2-yl)-methyl-amine 50 (K-i = 270 pM), and (3-phenylsulfonyl-5-methyl-7-metoxymethyl-pyrazolo[1,5-a]pyrimidin-2-yl)-methyl-amine 52 (K-i = 280 pM) are the most potent antagonists of the 5-HT6 receptors. (C) 2010 Elsevier Ltd. All rights reserved.
    DOI:
    10.1016/j.bmc.2010.12.055
点击查看最新优质反应信息

文献信息

  • SUBSTITUTED 3-ARYLSULFONYL-PYRAZOLO[1,5-A]PYRIMIDINES, SEROTONIN 5-HT6 RECEPTOR ANTAGONISTS AND METHODS FOR THE PRODUCTION AND USE THEREOF
    申请人:Ivashchenko Andrey Alexandrovich
    公开号:US20110178078A1
    公开(公告)日:2011-07-21
    The invention relates to the novel substituted 3-arylsulfonyl-pyrazolo[1,5-a]pyrimidines of the general formula 1, pharmaceutically acceptable salts and/or hydrates thereof, serotonin 5-HT 6 receptor antagonists and pharmaceutical compositions, and also to method for prophylaxis and treatment of various diseases of central nervous system at humans and warm-blooded animals pathogenesis of which is associated with serotonin 5-HT 6 receptors, in particular, Alzheimer's disease, Parkinson's disease, Huntington's disease, schizophrenia, and other neurodegenerative diseases, cognitive disorders and obesity. In the general formula 1: wherein: X═S, SO or NH; R 1 represents hydrogen, optionally substituted C 1 -C 3 alkyl, cycloalkyl, adamantyl, aryl or heterocyclyl; R 2 represents hydrogen, halogen, optionally substituted C 1 -C 3 alkyl, substituted hydroxyl, aryldiazenyl or optionally substituted amino group; R 3 represents hydrogen, optionally substituted C 1 -C 3 alkyl, substituted hydroxyl, pyridyl or optionally substituted amino group, besides, in cases when X═S or X═NH, at least one of R 1 , R 2 or R 3 represent substituted C 1 -C 3 alkyl, cycloalkyl, adamantyl, aryl, heterocyclyl, halogen, substituted hydroxyl, optionally substituted amino group, aryldiazenyl, or at least two of R 1 , R 2 or R 3 represent hydrogen; R 4 represents C 1 -C 3 alkyl; R 5 represents hydrogen, one or two halogens, C 1 -C 3 alkyl or optionally substituted hydroxyl.
    该发明涉及新的取代的3-芳基磺酰基吡唑并[1,5-a]嘧啶,其通式为1,其药学上可接受的盐和/或水合物,血清素5-HT6受体拮抗剂和制药组合物,以及用于预防和治疗与血清素5-HT6受体相关的中枢神经系统各种疾病的方法,特别是阿尔茨海默病、帕金森病、亨廷顿病、精神分裂症和其他神经退行性疾病、认知障碍和肥胖症。在通式1中:其中:X═S、SO或NH;R1代表氢、可选取代的C1-C3烷基、环烷基、金刚烷基、芳基或杂环基;R2代表氢、卤素、可选取代的C1-C3烷基、取代的羟基、芳基重氮基或可选取代的氨基基团;R3代表氢、可选取代的C1-C3烷基、取代的羟基、吡啶基或可选取代的氨基基团,此外,在X═S或X═NH的情况下,至少有R1、R2或R3中的一个代表取代的C1-C3烷基、环烷基、金刚烷基、芳基、杂环基、卤素、取代的羟基、可选取代的氨基基团、芳基重氮基,或者R1、R2或R3中的至少两个代表氢;R4代表C1-C3烷基;R5代表氢、一个或两个卤素、C1-C3烷基或可选取代的羟基。
  • [EN] SUBSTITUTED 3-ARYLSULFONYL-PYRAZOLO[1,5-A]PYRIMIDINES, SEROTONIN 5-HT6 RECEPTOR ANTAGONISTS AND METHODS FOR THE PRODUCTION AND USE THEREOF<br/>[FR] 3-ARYLSULFONYL-PYRAZOLO[1,5-A]PYRIMIDINES SUBSTITUÉES, ANTAGONISTES DES RÉCEPTEURS 5-HT6 DE SÉROTONINE, PROCÉDÉS DE FABRICATION ET D'UTILISATION
    申请人:IVASHCHENKO ANDREY ALEXANDROVICH
    公开号:WO2010041983A1
    公开(公告)日:2010-04-15
    Данное изобретение относится к новым замещенным 3-apилcyльфoнил-пиpaзoлo[1,5-a]пиpимидинaм общей формулы 1, их фармацевтически приемлемым солям и/или гидратам, антагонистам серотониновых 5-HT6 рецепторов и фармацевтическим композициям, а также способу лечения и предупреждения развития различных заболеваний центральной нервной системы у людей и теплокровных животных, патогенез которых связан с 5-HT6 рецепторами, в частности, болезни Альцгеймера, болезни Паркинсона, болезни Гантингтона, шизофрении, других нейродегенеративных заболеваний, когнитивных расстройств и ожирения. В общей формуле 1: где: X = S, SO или NH; R1 представляет собой атом водорода, необязательно замещенный С1-С3алкил, циклоалкил, адамантил, арил или гетероциклил; R2 представляет собой атом водорода, атом галогена, необязательно замещенный С1-С3алкил, замещенный гидроксил, арилдиазенил или необязательно замещенную аминогруппу; R3 представляет собой атом водорода, необязательно замещенный С1-С3алкил, замещенный гидроксил, пиридил или необязательно замещенную аминогруппу, причем, в случаях, когда X = S или X = NH, по крайней мере, один из R1, R2 или R3 представляет собой замещенный С1-С3алкил, циклоалкил, адамантил, арил, гетероциклил, атом галогена, замещенный гидроксил, необязательно замещенную аминогруппу, арилдиазенил или, по крайней мере, два из R1, R2 или R3 представляют собой атом водорода; R4 представляет собой С1-С3алкил; R5 представляет собой атом водорода, один или два атома галогена, С1-С3алкил или необязательно замещенный гидроксил.
    This invention relates to new substituted 3-arylcylyl-pyrazolo [1,5-a] pyrimidines of general formula 1, their pharmaceutically acceptable salts and/or hydrates, antagonists of serotonin 5-HT6 receptors and pharmaceutical compositions, as well as a method of treating and preventing the development of various central nervous system diseases in humans and warm-blooded animals, the pathogenesis of which is associated with 5-HT6 receptors, in particular Alzheimer's disease, Parkinson's disease, Huntington's disease, schizophrenia, other neurodegenerative diseases, cognitive disorders, and obesity. In general formula 1: where: X = S, SO or NH; R1 represents a hydrogen atom, optionally substituted with C1-C3 alkyl, cycloalkyl, adamantyl, aryl or heterocycle; R2 represents a hydrogen atom, a halogen atom, optionally substituted with C1-C3 alkyl, substituted with hydroxyl, aryl diazenyl or optionally substituted amino group; R3 represents a hydrogen atom, optionally substituted with C1-C3 alkyl, substituted with hydroxyl, pyridyl or optionally substituted amino group, wherein in cases where X = S or X = NH, at least one of R1, R2 or R3 represents a substituted C1-C3 alkyl, cycloalkyl, adamantyl, aryl, heterocycle, halogen atom, substituted hydroxyl, optionally substituted amino group, aryl diazenyl or at least two of R1, R2 or R3 represent a hydrogen atom; R4 represents C1-C3 alkyl; R5 represents a hydrogen atom, one or two halogen atoms, C1-C3 alkyl or optionally substituted hydroxyl.
  • SUBSTITUTED 3-ARYLSULFONYL-PYRAZOLO[1,5-A]PYRIMIDINES, SEROTONIN 5-HT6 RECEPTOR ANTAGONISTS AND METHODS FOR THE PRODUCTION AND USE THEREOF AND METHODS FOR THE PRODUCTION AND USE THEREOF
    申请人:Alla Chem, LLC.
    公开号:EP3020719B1
    公开(公告)日:2017-09-20
  • Synthesis and SAR of 3-arylsulfonyl-pyrazolo[1,5-a]pyrimidines as potent serotonin 5-HT6 receptor antagonists
    作者:Alexandre V. Ivachtchenko、Elena S. Golovina、Madina G. Kadieva、Volodymyr M. Kysil、Oleg D. Mitkin、Sergey E. Tkachenko、Ilya Okun
    DOI:10.1016/j.bmc.2010.12.055
    日期:2011.2
    Syntheses of a series of novel 3-sulfonyl-pyrazolo[1,5-a]pyrimidines and their 5-HT6 receptor antagonistic structure-activity relationship are disclosed. The nature and position of substituents, which affect their receptor antagonistic activity, are analyzed. Among all synthesized derivatives, 3-(3-chlorophenylsulfonyl)-5,7-dimethyl-pyrazolo[1,5-a]pyrimidin-2-yl}-methyl-amine 33 (K-i = 190 pM), (3-phenylsulfonyl-7-methyl-pyrazolo[1,5-a]pyrimidin-2-yl)-methyl-amine 44 (K-i = 240 pM), (3-phenylsulfonyl-5-metoxymethyl-7-methyl-pyrazolo[1,5-a]pyrimidin-2-yl)-methyl-amine 50 (K-i = 270 pM), and (3-phenylsulfonyl-5-methyl-7-metoxymethyl-pyrazolo[1,5-a]pyrimidin-2-yl)-methyl-amine 52 (K-i = 280 pM) are the most potent antagonists of the 5-HT6 receptors. (C) 2010 Elsevier Ltd. All rights reserved.
查看更多

同类化合物

阿拉格列汀 间型霉素环-3',5'-单磷酸酯 西地那非杂质 苯,[(1-甲基环戊基)硫代]- 苄基-(6-氯-1-甲基-1H-吡唑并[3,4-d]嘧啶-4-基)-胺 甲基-(6-甲基磺酰基-1(2)H-吡唑并[3,4-d]嘧啶-4-基)-胺 环己基-(1-甲基-1H-吡唑并[3,4-d]嘧啶-4-基)-胺 氮杂环庚-1-基-[7-氯-4-噻吩-2-基-2-(三氟甲基)-1,5,9-三氮杂双环[4.3.0]壬-2,4,6,8-四烯-8-基]甲酮 异丙基 4-(1-甲基-7-氧代-3-丙基-6,7-二氢-1H-吡唑并[4,3-d]嘧啶-5-基)噻吩-2-基磺酰基氨基甲酸酯 吡啶-2-基-[7-吡啶-4-基-吡唑[1,5-a]嘧啶-3-基]甲酮 吡唑并[2,3-a]嘧啶 吡唑并[1,5-a]嘧啶-7-胺 吡唑并[1,5-a]嘧啶-7(1h)-酮 吡唑并[1,5-a]嘧啶-6-醇 吡唑并[1,5-a]嘧啶-6-羧酸乙酯 吡唑并[1,5-a]嘧啶-6-羧酸 吡唑并[1,5-a]嘧啶-5-羧酸 吡唑并[1,5-a]嘧啶-3-胺盐酸盐(1:1) 吡唑并[1,5-a]嘧啶-3-胺;三氟乙酸 吡唑并[1,5-a]嘧啶-3-羰酰氯 吡唑并[1,5-a]嘧啶-3-羧酸乙酯 吡唑并[1,5-a]嘧啶-3-羧酸 吡唑并[1,5-a]嘧啶-3-磺酰胺 吡唑并[1,5-a]嘧啶-3-甲酰胺 吡唑并[1,5-a]嘧啶-3-甲腈 吡唑并[1,5-a]嘧啶-2-羧酸乙酯 吡唑并[1,5-a]嘧啶-2-羧酸 吡唑并[1,5-a]嘧啶,2-甲基-6-(1-甲基乙基)- 吡唑并[1,5-a]嘧啶,2-溴-5,7-二甲基- 吡唑并[1,5-A]嘧啶-5-胺 吡唑并[1,5-A]嘧啶-5(4H)-酮 吡唑并[1,5-A]嘧啶-3-甲醛 吡唑[1,5-A]嘧啶-5-羧酸甲酯 吡唑[1,5-A]嘧啶-5,7(4H,6H)-二酮 双氯地那非 别嘌醇 别嘌呤醇D2 二硫代乙基碳萘甲醚 二硫代-脱甲基-昔多芬 乙基7-甲基吡唑并[1,5-a]嘧啶-6-羧酸酯 [1,2]恶唑并[4,3-e]吡唑并[1,5-A]嘧啶 [(2S,5R)-5-(4-氨基-1H-吡唑并[3,4-d]嘧啶-1-基)四氢呋喃-2-基]甲醇 VEGFR2激酶抑制剂IV N5-(6-氨基己基)-N7-苄基-3-异丙基吡唑并[1,5-a]嘧啶-5,7-二胺 N5-(1-环庚基-1H-吡唑并[3,4-d]嘧啶-6-基)吡啶-2,5-二胺 N3-(4-氟苯基)-1H-吡唑并[3,4-D]嘧啶-3,4-二胺 N-苄基-6-氯-1H-吡唑并[3,4-d]嘧啶-4-胺 N-苄基-1H-吡唑并[3,4-d]嘧啶-4-胺 N-甲基-1H-吡唑并[3,4-d]嘧啶-4-胺 N-[2-(3-氨基-3-氧代丙氧基)乙基]-6-(4-溴苄基)吡唑并[1,5-a]嘧啶-3-甲酰胺